MAP2K7 and melanoma: The advent of targeted therapies, including BRAFV600E inhibitors such as vemurafenib, dabrafenib, and encorafenib and inhibitors of MEK, including trametinib, cobimetinib, and binimetinib, have markedly improved clinical outcomes for patients with BRAF-mutant melanoma.